Dynavax appoints chief medical officer
This article was originally published in Scrip
Dynavax, a clinical-stage biopharmaceutical company developing products to treat infectious and inflammatory diseases, has appointed Dr Robert Janssen chief medical officer. Prior to joining Berkeley, California-based Dynavax, Dr Janssen was vice-president of medical affairs at Gilead. He also spent 23 years at the US Centers for Disease Control and Prevention (CDC), most recently as the director of the Division of HIV/AIDS Prevention.
You may also be interested in...
A rush in the 2010s of high-tech and digital companies focused on women’s health and wellbeing are maturing, adding weight to the more traditional women's health market that has struggled to get attention from investors in the past.
An interactive look at recent executive-level company changes and promotions in the biopharma, medical device and diagnostics industries.
A selection of articles you might have missed from September 2020, including exclusive interviews with industry leaders and a review of value-based contract approaches in the US.